Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Liabilities (2016 - 2025)

ImmunityBio (IBRX) has disclosed Total Liabilities for 13 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 14.97% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 14.97% year-over-year, with the annual reading at $1.0 billion for FY2025, 14.97% up from the prior year.
  • Total Liabilities for Q4 2025 was $1.0 billion at ImmunityBio, down from $1.0 billion in the prior quarter.
  • The five-year high for Total Liabilities was $1.1 billion in Q2 2024, with the low at $394.8 million in Q1 2021.
  • Average Total Liabilities over 5 years is $842.3 million, with a median of $873.1 million recorded in 2023.
  • The sharpest move saw Total Liabilities skyrocketed 1516.03% in 2021, then decreased 20.11% in 2024.
  • Over 5 years, Total Liabilities stood at $712.8 million in 2021, then grew by 13.94% to $812.2 million in 2022, then skyrocketed by 34.26% to $1.1 billion in 2023, then decreased by 20.11% to $871.1 million in 2024, then increased by 14.97% to $1.0 billion in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $1.0 billion, $1.0 billion, and $971.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.